- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07685522
Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.
The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Shawn M Patterson
- Numéro de téléphone: 7164323545
- E-mail: spatterson@egrethealthcareventure.com
Sauvegarde des contacts de l'étude
- Nom: Erin M Garcia
- Numéro de téléphone: 716-863-2552
- E-mail: egarcia@egrethealthcareventures.com
Lieux d'étude
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Pologne, 61-848
- Pas encore de recrutement
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
-
Chercheur principal:
- Aleksander Araszkiewicz, Professor, MD, PhD
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Pologne, 31-202
- Recrutement
- Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
-
Chercheur principal:
- Grzegorz Kopeć, Professor, MD, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Subjects must meet all following general inclusion criteria:
- Age ≥ 18 and ≤ 75 years.
- Clinical signs, symptoms, and presentation consistent with acute PE;
- PE symptom duration ≤ 14 days;
- CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
- RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
- Systolic blood pressure ≥ 90 mmHg;
- Stable heart rate < 130 BPM prior to procedure;
- Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
- Informed Consent Form signed
- Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit
Exclusion Criteria:
Subjects must not meet any of the following general exclusion criteria:
- Thrombolytic use within 30 days of baseline CT angiogram
- Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
- Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
- Hematocrit < 28%;
- Platelets < 100,000/ML;
- Serum creatinine > 1.8 mg/dL;
- International normalized ratio (INR) > 3;
- Major trauma injury severity score (ISS) > 15 within the past 14 days
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
- Cardiovascular or pulmonary surgery within last 7 days;
- Actively progressing cancer requiring chemotherapy
- Known bleeding diathesis or coagulation disorder;
- Left bundle branch block;
- History of severe or chronic pulmonary arterial hypertension;
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
- History of uncompensated heart failure;
- History of underlying lung disease that is oxygen dependent;
- History of chest irradiation;
- History of heparin-induced thrombocytopenia (HIT);
- Patients who are under intubation
- Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
- Life expectancy of < 90 days, as determined by Investigator;
- Female who is pregnant or nursing;
- Current participation in another investigational drug or device treatment study
- History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
- Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Faisabilité de l'appareil
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
|
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety Endpoint: Major Adverse Events
Délai: 48 hours
|
Major Adverse Events, a composite of:
|
48 hours
|
|
Efficacy Endpoint: Reduction in RV/LV Ratio
Délai: 48 hours
|
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
|
48 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety Endpoint: Device-Related Death
Délai: 48 hours
|
Device-related death within 48 hours
|
48 hours
|
|
Safety Endpoint: Major Bleeding
Délai: 48 Hours
|
Major bleeding within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Clinical Deterioration
Délai: 48 Hours
|
Device-related clinical deterioration within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Pulmonary Vascular Injury
Délai: 48 Hours
|
Device-related pulmonary vascular injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Cardiac Injury
Délai: 48 Hours
|
Cardiac injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Any-Cause Mortality
Délai: 30 Days
|
Any-cause mortality within 30 days
|
30 Days
|
|
Safety Endpoint: Device-Related Serious Adverse Event
Délai: 30 Days
|
Device-related Serious Adverse Events (SAEs) within 30 days
|
30 Days
|
|
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
Délai: 30 Days
|
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
|
30 Days
|
|
Efficacy Endpoint: Modified Miller Index Score
Délai: 48 Hours
|
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
|
48 Hours
|
|
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
Délai: Procedure
|
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Change in Cardiac Index
Délai: Procedure
|
Procedural change in cardiac index [measured in L/min/m^2]
|
Procedure
|
|
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
Délai: 30 Days
|
Length of stay in the ICU associated with the index procedure [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Length of Total Hospital Stay
Délai: 30 Days
|
Length of total hospital stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
Délai: 30 Days
|
Post-index-procedure hospital length of stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
Délai: Procedure
|
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
Délai: Procedure
|
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
Délai: Procedure
|
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
|
Procedure
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Délai: 48 Hours
|
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
|
48 Hours
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
Délai: 30 Days
|
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
|
30 Days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 26-VIC-0001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .